Screener
Allogene Therapeutics ALLO Business Segments — Facilities & IT-related spend
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept allo:FacilitiesAndITRelatedExpense.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cema-cel | $7,669 | $6,222 |
| All other development costs | 1,999 | 10,390 |
| Payroll | 14,444 | 19,601 |
| Facilities & IT-related spend | 6,418 | 7,319 |
| Supporting external spend | 4,372 | 5,846 |
| Other operating expenses | 11,190 | 15,813 |
| Total operating expenses | 46,092 | 65,191 |
| Other income (expenses), net | 3,485 | 5,458 |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's business segments — facilities & it-related spend?
- Allogene Therapeutics (ALLO) reported business segments — facilities & it-related spend of $6.42M in Q1 2026.
- How has Allogene Therapeutics's business segments — facilities & it-related spend changed year-over-year?
- Allogene Therapeutics's business segments — facilities & it-related spend decreased by 12.3% year-over-year, from $7.32M to $6.42M.
- What is the long-term trend for Allogene Therapeutics's business segments — facilities & it-related spend?
- Over 2 years (2023 to 2025), Allogene Therapeutics's business segments — facilities & it-related spend has grown at a -8.2% compound annual growth rate (CAGR), from $33.67M to $28.41M.
- What does business segments — facilities & it-related spend mean?
- This metric tracks the overhead costs associated with physical infrastructure, laboratory space, and information technology systems required to support business operations. It represents the fixed cost base necessary to maintain the company's research and administrative environment. Managing these expenses is critical for maintaining operational efficiency in a capital-intensive biotech model.
Ask your AI about Allogene Therapeutics's business segments — facilities & it-related spend.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude